Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Adopts Cures Bill By Big Margin; FDA Could Tap $20m More In 2017

Executive Summary

The Senate approved the same 21st Century Cures bill passed by the House last week on a 94-5 tally; the bill is expected to be quickly signed by President Obama. Provisions for extra dollars for FDA in the bill means that even with a plan by Congress to adopt a continuing resolution this week freezing FDA funding until April 28, the agency can rely on an additional $20 million set aside for it in Cures in the new year.

You may also be interested in...



FDA Will No Longer Regulate Certain Medical Software

The US agency published a final rule on 16 April that says eight medical software functions will no longer be classified as medical devices. The rule finalizes a statutory provision from the 21st Century Cures Act.

Trump Praises Record Device Approvals, Pushes Congress To Pass 'Right-To-Try' Bills

In his Jan. 30 State of the Union address, President Trump praised US FDA for its high approval rate of devices and drugs in 2017, and urged Congress to do more by approving 'right-to-try' legislation that he says would allow terminally ill patients to gain access to experimental devices and drugs.

'Least Burdensome' Comment Deadline Delayed By US FDA

The deadline has been bumped back to mid-March following a request from industry trade group AdvaMed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel